10-Year study tracks safety of new silicone breast implants

NCT ID NCT06013514

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This study follows 60 women aged 18 to 65 who receive Nagor PERLE silicone breast implants for breast reconstruction, augmentation, or revision surgery. Researchers will monitor complications like capsular contracture (hardening) and implant rupture over 10 years. The goal is to gather long-term safety and performance data on these implants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Nagor PERLE silicone breast implants

What this could lead to

If successful, this study could confirm that these implants are safe and effective for breast reconstruction, augmentation, or revision over the long term.

What could go wrong

This is an observational study, not a controlled trial, so it cannot prove cause and effect. Complications like capsular contracture or rupture may still occur, and results may not apply to all patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST RECONSTRUCTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • NHS Manchester

    RECRUITING

    Manchester, M13 9WL, United Kingdom

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••